产品说明书

Hydroxy Itraconazole

Print
Chemical Structure| 112559-91-8 同义名 : Itraconazole metabolite Hydroxy Itraconazole;R-63373;hydroxy-ITZ;OH-ITZ
CAS号 : 112559-91-8
货号 : A343771
分子式 : C35H38Cl2N8O5
纯度 : 99%+
分子量 : 721.633
MDL号 : MFCD28964104
存储条件:

粉末 Inert atmosphere,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 85 mg/mL(117.79 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 Hydroxy itraconazole is an active metabolite of Itraconazole (ITZ), which is a triazole antifungal agent.
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02633709 Spinal Muscular Atrophy Phase 1 Completed - Netherlands ... 展开 >> Pra International Group B.V Groningen, Netherlands, 9728 NZ 收起 <<
NCT02093728 Solid Tumours Phase 1 Completed - United States, Kansas ... 展开 >> Research Site Overland Park, Kansas, United States 收起 <<
NCT02157883 Advanced Non Small Cell Lung C... 展开 >>ancer Advanced (Inoperable) Non Small Cell Lung Cancer 收起 << Phase 1 Active, not recruiting December 31, 2018 United States, California ... 展开 >> Research Site San Diego, California, United States, 92123 United States, Ohio Research Site Cleveland, Ohio, United States, 44106-4950 Belgium Research Site Edegem, Belgium, 2650 Research Site Gent, Belgium, 9000 Korea, Republic of Research Site Seongnam-si, Korea, Republic of, 13620 Research Site Seoul, Korea, Republic of, 03080 Research Site Seoul, Korea, Republic of, 03722 Research Site Seoul, Korea, Republic of, 06351 Research Site Seoul, Korea, Republic of, 138-736 Netherlands Research Site Amsterdam, Netherlands, 1066 CX Research Site Maastricht, Netherlands, 6229 HX Research Site Rotterdam, Netherlands, 3015 CE Taiwan Research Site Taipei, Taiwan, 10002 Research Site Taipei, Taiwan, 11217 United Kingdom Research Site London, United Kingdom, SE1 9RT Research Site Manchester, United Kingdom, M20 4BX 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.39mL

0.28mL

0.14mL

6.93mL

1.39mL

0.69mL

13.86mL

2.77mL

1.39mL

参考文献

[1]Mino Y, Naito T, et al. Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole. Clin Chim Acta. 2013 Jan 16;415:128-32.